The safety and efficacy of phage therapy for bone and Joint Infections: a systematic review
The safety and efficacy of phage therapy for bone and Joint Infections: a systematic review
Bacterial resistance to antibiotics has catalysed interest in alternative antimicrobial strategies. Bacteriophages (phages) are viruses of bacteria with a long history of successful therapeutic use. Phage therapy is a promising antibacterial strategy for infections with a biofilm component, including recalcitrant bone and joint infections, which have significant social, financial and human impacts. Here, we report a systematic review of the safety and efficacy of phage therapy for the treatment of bone and joint infections. Three electronic databases were systematically searched for articles that reported primary data about human phage therapy for bone and joint infections. Two authors independently assessed study eligibility and performed data extraction. Seventeen reports were eligible for inclusion in this review, representing the treatment of 277 patients. A cautionary, crude, efficacy estimate revealed that 93.1% (n = 258/277) achieved clinical resolution, 3.3% (n = 9/277) had improvement and 3.6% (n = 10/277) showed no improvement. Seven of the nine reports that directly commented on the safety of phage therapy did not express safety concerns. The adverse effects reported in the remaining two were not severe and were linked to the presence of contaminating endotoxins and pre-existing liver pathology in a patient treated with high-titre intravenous phage therapy. Three other reports, from 1940–1987, offered general comments on the safety of phage therapy and documented adverse effects consistent with endotoxin co-administration concomitant with the use of raw phage lysates. Together, the reports identified by this review suggest that appropriately purified phages represent a safe and highly efficacious treatment option for complex and intractable bone and joint infections
Clarke, Alex L.
2a74426d-d7d7-475f-8162-ed252bdddb2a
Soir, Stephen de
656710ac-efbf-4510-a427-0fc268c2d589
Jones, Joshua D.
c0199ae5-79fe-446b-a9ba-89921ae0ede2
10 November 2020
Clarke, Alex L.
2a74426d-d7d7-475f-8162-ed252bdddb2a
Soir, Stephen de
656710ac-efbf-4510-a427-0fc268c2d589
Jones, Joshua D.
c0199ae5-79fe-446b-a9ba-89921ae0ede2
Clarke, Alex L., Soir, Stephen de and Jones, Joshua D.
(2020)
The safety and efficacy of phage therapy for bone and Joint Infections: a systematic review.
Antibiotics, 9 (11), [795].
(doi:10.3390/antibiotics9110795).
Abstract
Bacterial resistance to antibiotics has catalysed interest in alternative antimicrobial strategies. Bacteriophages (phages) are viruses of bacteria with a long history of successful therapeutic use. Phage therapy is a promising antibacterial strategy for infections with a biofilm component, including recalcitrant bone and joint infections, which have significant social, financial and human impacts. Here, we report a systematic review of the safety and efficacy of phage therapy for the treatment of bone and joint infections. Three electronic databases were systematically searched for articles that reported primary data about human phage therapy for bone and joint infections. Two authors independently assessed study eligibility and performed data extraction. Seventeen reports were eligible for inclusion in this review, representing the treatment of 277 patients. A cautionary, crude, efficacy estimate revealed that 93.1% (n = 258/277) achieved clinical resolution, 3.3% (n = 9/277) had improvement and 3.6% (n = 10/277) showed no improvement. Seven of the nine reports that directly commented on the safety of phage therapy did not express safety concerns. The adverse effects reported in the remaining two were not severe and were linked to the presence of contaminating endotoxins and pre-existing liver pathology in a patient treated with high-titre intravenous phage therapy. Three other reports, from 1940–1987, offered general comments on the safety of phage therapy and documented adverse effects consistent with endotoxin co-administration concomitant with the use of raw phage lysates. Together, the reports identified by this review suggest that appropriately purified phages represent a safe and highly efficacious treatment option for complex and intractable bone and joint infections
This record has no associated files available for download.
More information
Accepted/In Press date: 5 November 2020
Published date: 10 November 2020
Identifiers
Local EPrints ID: 471943
URI: http://eprints.soton.ac.uk/id/eprint/471943
PURE UUID: b0f064bf-10e7-41c6-93c5-76bdce7dbd4c
Catalogue record
Date deposited: 22 Nov 2022 18:01
Last modified: 17 Mar 2024 04:13
Export record
Altmetrics
Contributors
Author:
Alex L. Clarke
Author:
Stephen de Soir
Author:
Joshua D. Jones
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics